• Vivus Inc., of Mountain View, Calif., responded to statements by First Manhattan Co. (FMC), a 9. 1 percent shareholder, alleging the launch of obesity drug Qsymia (phentermine/topiramate extended release) was mismanaged and Vivus did not adequately address out-of-pocket costs to patients and mismanaged the regulatory process for the drug, branded Qsiva, in the European Union.